Cargando…
The anti-leukemic activity of sodium dichloroacetate in p53(mutated/null) cells is mediated by a p53-independent ILF3/p21 pathway
B-chronic lymphocytic leukemia (B-CLL) patients harboring p53 mutations are invariably refractory to therapies based on purine analogues and have limited treatment options and poor survival. Having recently demonstrated that the mitochondria-targeting small molecule sodium dichloroacetate (DCA) exhi...
Autores principales: | Agnoletto, Chiara, Brunelli, Laura, Melloni, Elisabetta, Pastorelli, Roberta, Casciano, Fabio, Rimondi, Erika, Rigolin, Gian Matteo, Cuneo, Antonio, Secchiero, Paola, Zauli, Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385858/ https://www.ncbi.nlm.nih.gov/pubmed/25544776 |
Ejemplares similares
-
Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3
por: Agnoletto, Chiara, et al.
Publicado: (2014) -
Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1
por: Voltan, Rebecca, et al.
Publicado: (2016) -
The p53 transcriptional pathway is preserved in ATM(mutated) and NOTCH1(mutated) chronic lymphocytic leukemias
por: Athanasakis, Emmanouil, et al.
Publicado: (2014) -
The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
por: Secchiero, Paola, et al.
Publicado: (2017) -
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
por: Voltan, Rebecca, et al.
Publicado: (2016)